BIOMAT Database Logo BIOMAT Database Logo

Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1). 2021

Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.

Myeloid cell leukemia-1 (Mcl-1) protein is a family of Bcl-2 (B cell lymphoma 2) rich proteases of the most common increase threshold for genetic aberrations observed in human cancer, including lung, breast, pancreatic, cervical, and ovarian cancers as well as leukemia and lymphoma. Mcl-1 is recognized as an attractive drug target in number of diseases, including cancer. In the present study we surveyed and collected queries compounds from PDB database of Mcl-1 protein and generated pharmacophore-based models adapted to screen the drug-like compounds from FDA approved database. The 206 best lead molecules from pharmacophore-screening were further evaluated by molecular docking, molecular dynamics simulation, MM-GBSA calculation, as well as experimental validation. Two hits, ZINC00601272 and ZINC00002166, showed the best docking scores, which showed a tendency to inhibit cell viability of HL60 and K562 leukemia cells with Mcl-1 expressions. Conclusively, the present study provides structural information of Mcl-1 inhibitors for next generations of cancer therapeutics through computational and experimental validation approach.Communicated by Ramaswamy H. Sarma.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative
D022423 Myeloid Cells The classes of BONE MARROW-derived blood cells in the monocytic series (MONOCYTES and their precursors) and granulocytic series (GRANULOCYTES and their precursors). Cell, Myeloid,Cells, Myeloid,Myeloid Cell

Related Publications

Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation.
May 2021, Journal of molecular liquids,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Discovery of small molecules through pharmacophore modeling, docking and molecular dynamics simulation against Plasmodium vivax Vivapain-3 (VP-3).
May 2018, Heliyon,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Identification of new small molecule monoamine oxidase-B inhibitors through pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation studies.
January 2023, Journal of biomolecular structure & dynamics,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Discovery of novel natural products as dual MNK/PIM inhibitors for acute myeloid leukemia treatment: Pharmacophore modeling, molecular docking, and molecular dynamics studies.
January 2022, Frontiers in chemistry,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Molecular modeling and docking of small molecule inhibitors against NEK2.
January 2016, Bioinformation,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Discovery of Potential Inhibitors of Aldosterone Synthase from Chinese Herbs Using Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Studies.
January 2016, BioMed research international,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents.
January 2021, Current molecular medicine,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations.
December 2016, Journal of receptor and signal transduction research,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
In silico discovery of food-derived phytochemicals against asialoglycoprotein receptor 1 for treatment of hypercholesterolemia: Pharmacophore modeling, molecular docking and molecular dynamics simulation approach.
December 2023, Journal of molecular graphics & modelling,
Muhammad R Suleiman, and Hanxun Wang, and Danxia Huang, and Huibin Wang, and Johnson Joseph, and Tianci Huang, and Fengjiao Zhang, and Jian Wang, and Maosheng Cheng
Structure-based discovery of interleukin-33 inhibitors: a pharmacophore modelling, molecular docking, and molecular dynamics simulation approach.
December 2020, SAR and QSAR in environmental research,
Copied contents to your clipboard!